Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Sensory neuron BRAF mediates opioid-induced hyperalgesia and tolerance via presynaptic NMDA receptor hyperactivity
Daozhong Jin, Hong Chen, Yuying Huang, Shao-Rui Chen, Hui-Lin Pan
Daozhong Jin, Hong Chen, Yuying Huang, Shao-Rui Chen, Hui-Lin Pan
View: Text | PDF
Research Article Neuroscience Oncology

Sensory neuron BRAF mediates opioid-induced hyperalgesia and tolerance via presynaptic NMDA receptor hyperactivity

  • Text
  • PDF
Abstract

Opioids are essential analgesics for managing severe pain but can paradoxically increase pain sensitivity (hyperalgesia) and diminish analgesic efficacy (tolerance). Hyperactivity of NMDA-type glutamate receptors (NMDARs) at primary afferent terminals in the spinal cord contributes to both phenomena; however, the underlying signaling mechanisms remain unclear. Here, we report that morphine administration in rats promoted the translocation of monomeric BRAF, an oncogenic kinase, from the dorsal root ganglion (DRG) to spinal cord synaptosomes, leading to increased MEK-ERK phosphorylation at nociceptor central terminals. BRAF physically interacted with NMDARs in both rat and human spinal cords. Inhibition of BRAF activity with vemurafenib reversed morphine-induced NMDAR phosphorylation and synaptic localization of α2δ-1–bound NMDARs. Vemurafenib also abolished morphine-induced presynaptic NMDAR hyperactivity in spinal dorsal horn neurons. Correspondingly, conditional Braf knockout in DRG neurons normalized morphine-enhanced NMDAR phosphorylation, synaptic trafficking of α2δ-1–bound NMDARs, and NMDAR hyperactivity in the spinal cord. Furthermore, pharmacological inhibition of BRAF or MEK, or Braf deletion in DRG neurons, enhanced morphine analgesia while mitigating morphine-induced hyperalgesia and tolerance. These findings identify BRAF overactivity at nociceptor central terminals as a key mediator of opioid-induced NMDAR hyperactivity. Clinically approved BRAF inhibitors could be repurposed to enhance opioid analgesia while minimizing adverse effects.

Authors

Daozhong Jin, Hong Chen, Yuying Huang, Shao-Rui Chen, Hui-Lin Pan

×

Figure 8

Braf knockout in primary sensory neurons attenuates morphine-induced BRAF translocation as well as hyperalgesia and tolerance.

Options: View larger image (or click on image) Download as PowerPoint

Braf knockout in primary sensory neurons attenuates morphine-induced BR...
(A) Representative immunoblot images and quantification show BRAF protein expression in the DRG and spinal cord (SC) of conditional Braf knockout (cKO) and WT mice treated with saline (Sal) or morphine (Mor, 10 mg/kg, twice daily) for 7 days (n = 6 mice per group). Total and synaptosomal (Syn) proteins were extracted from lumbar DRG and dorsal spinal cord tissues for immunoblotting. GAPDH or PSD95 was used as a loading control. (B) Representative immunoblot images and quantification show the amount of pMEK and total MEK in the spinal cord from WT and Braf-cKO mice treated with saline or morphine (10 mg/kg, i.p., twice daily) for 7 consecutive days (n = 6 mice per group). Total and synaptosomal (Syn) proteins from the dorsal spinal cord were extracted for immunoblotting. (C) Time course of hyperalgesia and tolerance in WT (n = 11 mice) and Braf-cKO (n = 13 mice) treated with morphine (10 mg/kg, twice daily) for 7 days. Pressure withdrawal threshold and heat withdrawal latency were measured before (baseline) and 30 minutes after the first morphine (Mor) injection daily. (D) Time course of the acute analgesic effect produced by the first morphine injection on day 1 and day 7 in WT (n = 11 mice) and Braf-cKO (n = 13 mice). Data are expressed as means± SEM. In Panels A and B, **P < 0.01, ***P < 0.001 (1-way ANOVA followed by Tukey’s post hoc test). In C and D, *P < 0.05, **P < 0.01, ***P < 0.001 versus respective values at day 1 or time (min) 0. #P < 0.05, ###P < 0.001 versus respective WT groups at the same time point (2-way ANOVA followed by Tukey’s post hoc test).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts